TheraRadar

R-Pharm

Pre-Approval PRO BETA

Also known as: R-Pharm International, LLC, R-Pharm

52
Total Trials
22
Phase 3
20
Phase 2
11
Recruiting
543
Score

Pipeline by Phase

Phase 3
22
Phase 2
20
Phase 1
16

Therapeutic Focus

COVID-19 Rheumatoid Arthritis Healthy Metastatic Breast Cancer Familial Mediterranean Fever

Clinical Trials (52)

NCT05432960 Phase 3 WITHDRAWN

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Started: 12/1/2023

NCT05673902 Phase 3 ACTIVE NOT RECRUITING

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Started: 12/11/2020

NCT03120949 Phase 3 COMPLETED

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Started: 7/4/2017

NCT02760368 Phase 3 COMPLETED

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Started: 5/19/2016

NCT02760433 Phase 3 COMPLETED

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Started: 1/25/2017

NCT02760407 Phase 3 COMPLETED

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Started: 6/6/2016

NCT07625384 Phase 3 NOT YET RECRUITING

Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease

Started: 5/18/2026

NCT07670546 Phase 3 ACTIVE NOT RECRUITING

A Phase III Study of the Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica

Started: 6/11/2025

NCT07435324 Phase 3 ACTIVE NOT RECRUITING

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Started: 8/8/2024

NCT07386938 Phase 3 ACTIVE NOT RECRUITING

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Started: 8/9/2024

NCT03551210 Phase 3 COMPLETED

Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

Started: 5/4/2016

NCT04501783 Phase 3 COMPLETED

Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

Started: 5/20/2020

NCT03663374 Phase 3 COMPLETED

Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence

Started: 11/18/2014

NCT03575702 Phase 3 COMPLETED

Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.

Started: 7/18/2016

NCT02248961 Phase 3 COMPLETED

Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Started: 5/1/2014

NCT03833362 Phase 3 COMPLETED

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

Started: 5/7/2014

NCT03669484 Phase 3 COMPLETED

Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia

Started: 8/22/2017

NCT00883116 Phase 3 TERMINATED

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Started: 8/1/2009

NCT07517575 Phase 2 RECRUITING

Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

Started: 3/17/2023

NCT05190991 Phase 2 RECRUITING

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Started: 10/5/2021

NCT06440746 Phase 2 RECRUITING

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Started: 8/23/2023

NCT07553988 Phase 2 ACTIVE NOT RECRUITING

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Started: 10/24/2024

NCT05092776 Phase 2 ACTIVE NOT RECRUITING

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Started: 4/29/2021

NCT04692766 Phase 2 COMPLETED

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Started: 2/12/2020

NCT04380519 Phase 2 COMPLETED

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Started: 4/23/2020

NCT04246723 Phase 2 COMPLETED

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Started: 5/6/2019

NCT04067492 Phase 2 TERMINATED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

Started: 3/26/2018

NCT04686773 Phase 2 COMPLETED

Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention

Started: 3/5/2021

NCT04452474 Phase 2 WITHDRAWN

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

Started: 6/30/2020

NCT00723957 Phase 2 COMPLETED

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Started: 12/1/2008

NCT00983801 Phase 2 COMPLETED

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

Started: 11/1/2009

NCT03485846 Phase 2 COMPLETED

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Started: 11/27/2017

NCT00633464 Phase 2 COMPLETED

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Started: 6/1/2008

NCT00593827 Phase 2 COMPLETED

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

Started: 5/1/2008

NCT00490646 Phase 2 COMPLETED

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Started: 2/1/2008

NCT00546364 Phase 2 TERMINATED

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

Started: 2/1/2008

NCT07543744 Phase 1 RECRUITING

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

Started: 4/17/2025

NCT07206043 Phase 1 COMPLETED

Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

Started: 12/3/2024

NCT04246762 Phase 1 COMPLETED

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Started: 11/16/2021

NCT07435311 Phase 1 COMPLETED

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Started: 6/15/2020

NCT04760730 Phase 1 COMPLETED

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

Started: 7/13/2021

NCT04684446 Phase 1 COMPLETED

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

Started: 9/15/2021

NCT02667639 Phase 1 COMPLETED

Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects

Started: 1/1/2016

NCT00832117 Phase 1 COMPLETED

Phase I Combination Ixabepilone + Cisplatin

Started: 5/1/2009

NCT03832426 Phase 1 COMPLETED

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Started: 11/8/2013

NCT03537404 Phase 1 COMPLETED

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Started: 4/24/2017

NCT03659305 Phase 1 COMPLETED

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Started: 7/10/2018

NCT00568022 Phase 1 COMPLETED

A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Started: 2/1/2008

NCT00634088 Phase 1 TERMINATED

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Started: 6/1/2008

NCT00683904 Phase 1 COMPLETED

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Started: 6/1/2008

NCT00632424 Phase 1 TERMINATED

Phase 1 Trial of Oral Ixabepilone

Started: 5/1/2008

NCT07597668 Phase 1 ACTIVE NOT RECRUITING

A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

Started: 4/16/2025

Drug Candidates

RS-113, 160 mg RS-113, 240 mg RS-113, 320 mg OKZ q4w RPH-104 80 mg RPH-104 160 mg RPH-104 320 mg RPH-104 Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL) Olokizumab
Activity Status: Active
Last Trial Started: 5/18/2026
Last Trial Ended: 7/25/2025
Trials (12 months): 1
Completed Trials: 33
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.